SLC5A2 and pyelonephritis: In a multicenter study of 347 KTRs on SGLT‐2 inhibitors, the incidence of UTIs was only 6.6% over a year, and no serious urosepsis or pyelonephritis cases were attributed to SGLT‐2 inhibitors [55].